Intratumoral heterogeneity and consequences for targeted therapies

Bulletin du Cancer

Volumn 102, Issue 1, 2015, Pages 17-23

  Turtoi, Andrei ^a   Blomme, Arnaud ^a   Castronovo, Vincent ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Drug resistance; Gene mutation; MALDI imaging; Proteomics; Tumor relapse

Indexed keywords

PROTEIN; GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ARTICLE; CANCER CELL; CANCER RECURRENCE; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; EVOLUTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENOTYPE; HISTORY OF MEDICINE; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; PHENOTYPE; PROTEOMICS; STROMA; ADAPTATION; CELL SURVIVAL; GENETICS; MOLECULAR EVOLUTION; MUTATION; NEOPLASMS; PATHOLOGY; PHYSIOLOGY;

ADAPTATION, PHYSIOLOGICAL; CELL SURVIVAL; EVOLUTION, MOLECULAR; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PHENOTYPE; PROTEOMICS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR;

EID: 84927544635     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1016/j.bulcan.2014.12.006     Document Type: Review

References (52)

1. Hauschka TS. The chromosomes in ontogeny and oncogeny. Cancer Res 1961;21:957-74.
2. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194(4260):23-8.
3. Diaz Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486(7404):537-40.
4. Navin N, Kendall J, Troge J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011;478(7341):90-4.
5. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366(10):883-92.
6. Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011;20(6):810-7.
7. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486 (7403):400-4.
8. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013;500(7463):415-21.
9. Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003;348(9):791-9.
10. Pfeifer GP, Denissenko MF, Olivier M, et al. Tobacco smoke carcinogens. DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002;21(48):7435-51.
11. Dumaz N, Drougard C, Sarasin A, et al. Specific UV-induced mutation spectrum in the p53 gene of skin tumors from DNA-repair-deficient xeroderma pigmentosum patients. Proc Natl Acad Sci U S A 1993;90:10529-33.
12. Theillet C. Towards an inventory of oncogenic mutations in cancer. Bull Cancer 2010;97 (11):1223-9.
13. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012;150:1121-34.
14. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012;486(7403):395-9.
15. Navin N, Hicks J. Future medical applications of single-cell sequencing in cancer. Genome Med 2011;3(5):31.
16. Bedard PL, Hansen AR, Ratain MJ, et al. Tumour heterogeneity in the clinic. Nature 2013;501(7467):355-64.
17. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012;72:4875-82.
18. Chen ZY, Zhong WZ, Zhang XC, et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist 2012; 17:978-85.
19. Nik-Zainal S, Van Loo P, Wedge DC, et al. The life history of 21 breast cancers. Cell 2012; 149:994-1007.
20. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009;9:302-12.
21. Banys M, Gruber I, Krawczyk N, et al. Hematogenous and lymphatic tumor cell dissemination may be detected in patients diagnosed with ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2012;131:801-8.
22. Hüsemann Y, Geigl JB, Schubert F, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008;13:58-68.
23. Sänger N, Effenberger KE, Riethdorf S, et al. Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int J Cancer 2011;129:2522-6.
24. Klein CA, Blankeinstein TJ, Schmidt-Kittler O, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002;360:683-9.
25. Schardt JA, Meyer M, Hartmann CH, et al. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 2005;8:227-39.
26. Schmidt-Kittler O, Ragg T, Daskalakis A, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A 2003;100:7737-42.
27. Murez T, Droupy S, Rebillard X, et al. Circulating tumor cells and advanced prostate cancer. Bull Cancer 2012;99:S4-15.
28. Weckermann D, Polzer B, Ragg T, et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol 2009;27: 1549-56.
29. Lindström LS, Karisson E, Wilking UM, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012;30:2601-8.
30. Liedtke C, Broglio K, Moulder S, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009;20:1953-8.
31. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21: 309-22.
32. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 2010;18:884-901.
33. Wilson TR, Fridlyand J, Yan Y, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012;487:505-9.
34. Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500-4.
35. Crawford Y, Kasman I, Yu L, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009;15:21-34.
36. Gilbert LA, Hemann MT. DNA damagemediated induction of a chemoresistant niche. Cell 2010;143:355-66.
37. Landsberg J, Kohlmeyer J, Renn M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012;490:412-6.
38. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013;501(7467): 346-54.
39. Hafner C, Lopez-Knowles E, Luis NM, et al. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci U S A 2007;104:13450-54.
40. Hafner C, Toll A, Fernandez-Casado A, et al. Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. Proc Natl Acad Sci U S A 2010;107:20780-85.
41. Bos PD, Zhang XH, Nadal C, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009;459:1005-9.
42. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
43. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
44. Jones EA, Schmitz N, Waaijer CJ, et al. Imaging mass spectrometry-based molecular histology differentiates microscopically identical and heterogeneous tumors. J Proteome Res 2013;12(4):1847-55.
45. Balluff B, Frese CK, Maier SK, et al. De novo discovery of phenotypic intra-tumor heterogeneity using imaging mass spectrometry. J Pathol 2015;235(5):3-13.
46. Le Faouder J, Laouirem S, Alexandrov T, et al. Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometry. Proteomics 2014;14(7-8):965-72.
47. Sugihara Y, Taniguchi H, Kushima R, et al. Laser microdissection and two-dimensional difference gel electrophoresis reveal proteomic intra-tumor heterogeneity in colorectal cancer. J Proteomics 2013;78:134-47.
48. Turtoi A, Blomme A, Debois D, et al. Organized proteomic heterogeneity in colorectal cancer liver metastases and implications for therapies. Hepatology 2014;59(3):924-34.
49. Turtoi A, De Pauw E, Castronovo V. Innovative proteomics for the discovery of systemically accessible cancer biomarkers suitable for imaging and targeted therapies. Am J Pathol 2011;178(1):12-8.
50. Krall N, Scheuermann J, Neri D. Small targeted cytotoxics: current state and promises from DNA-encoded chemical libraries. Angew Chem Int Ed Engl 2013;52(5):1384-402.
51. Smaglo BG, Aldeghaither D, Weiner LM. The development of immunoconjugates for targeted cancer therapy. Nat Rev Clin Oncol 2014;11(11):637-48.
52. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367 (19):1783-91.